Log In
BCIQ
Print this Print this
 

Amaryl, glimepiride

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionSulfonylurea ATP-dependent potassium channel (KATP) blocker
Molecular Target ATP-dependent potassium channel (KATP)
Mechanism of ActionATP-dependent potassium channel (KATP) blocker
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes; Treat Type II diabetics with ischemic heart disease
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today